{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,23]],"date-time":"2026-07-23T15:03:19Z","timestamp":1784818999383,"version":"3.55.0"},"reference-count":76,"publisher":"MDPI AG","issue":"20","license":[{"start":{"date-parts":[[2022,10,19]],"date-time":"2022-10-19T00:00:00Z","timestamp":1666137600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Cancers"],"abstract":"<jats:p>Cutaneous melanoma is a relatively common neoplasm, with fairly well understood pathogenesis, risk factors, prognosis and therapeutic protocols. The incidence of this disease is increasing every year. The situation is different for rare malignancies such as vulvar melanomas and for the even rarer vaginal melanomas. The risk factors for vulvovaginal tumors are not fully understood. The basis of treatment in both cases is surgical resection; however, other types of treatments such as immunotherapy are available. This paper focuses on comparing the pathogenesis and risk factors associated with these neoplasms as well as the efficacy of two groups of drugs\u2014anti-PD-L1 and anti-CTLA4 inhibitors\u2014against both cutaneous melanoma and melanoma of the lower genital tract (vulva and vagina). In the case of cutaneous melanoma, the situation looks more optimistic than for vulvovaginal melanoma, which has a much worse prognosis and, as it turns out, shows a poorer response to immune therapy.<\/jats:p>","DOI":"10.3390\/cancers14205123","type":"journal-article","created":{"date-parts":[[2022,10,19]],"date-time":"2022-10-19T20:32:23Z","timestamp":1666211543000},"page":"5123","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":17,"title":["Cutaneous Melanoma versus Vulvovaginal Melanoma\u2014Risk Factors, Pathogenesis and Comparison of Immunotherapy Efficacy"],"prefix":"10.3390","volume":"14","author":[{"given":"Anna","family":"Lorenz","sequence":"first","affiliation":[{"name":"Department of Gynecological Surgery and Gynecological Oncology of Adults and Adolescents, Pomeranian Medical University in Szczecin, al. Powsta\u0144c\u00f3w Wielkopolskich 72, 70-111 Szczecin, Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1176-2153","authenticated-orcid":false,"given":"Mateusz","family":"Koz\u0142owski","sequence":"additional","affiliation":[{"name":"Department of Gynecological Surgery and Gynecological Oncology of Adults and Adolescents, Pomeranian Medical University in Szczecin, al. Powsta\u0144c\u00f3w Wielkopolskich 72, 70-111 Szczecin, Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sebastian","family":"Lenkiewicz","sequence":"additional","affiliation":[{"name":"Department of Gynecological Surgery and Gynecological Oncology of Adults and Adolescents, Pomeranian Medical University in Szczecin, al. Powsta\u0144c\u00f3w Wielkopolskich 72, 70-111 Szczecin, Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sebastian","family":"Kwiatkowski","sequence":"additional","affiliation":[{"name":"Department of Obstetrics and Gynecology, Pomeranian Medical University in Szczecin, al. Powsta\u0144c\u00f3w Wielkopolskich 72, 70-111 Szczecin, Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aneta","family":"Cymbaluk-P\u0142oska","sequence":"additional","affiliation":[{"name":"Department of Gynecological Surgery and Gynecological Oncology of Adults and Adolescents, Pomeranian Medical University in Szczecin, al. Powsta\u0144c\u00f3w Wielkopolskich 72, 70-111 Szczecin, Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2022,10,19]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"971","DOI":"10.1016\/S0140-6736(18)31559-9","article-title":"Melanoma","volume":"392","author":"Schadendorf","year":"2018","journal-title":"Lancet"},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"816","DOI":"10.1016\/S0140-6736(13)60802-8","article-title":"Cutaneous melanoma","volume":"383","author":"Eggermont","year":"2014","journal-title":"Lancet"},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"2179","DOI":"10.1016\/j.ejca.2015.07.039","article-title":"Survival of patients with skin melanoma in Europe increases further: Results of the EUROCARE-5 study","volume":"51","author":"Crocetti","year":"2015","journal-title":"Eur. J. Cancer"},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1016\/j.ejca.2003.09.030","article-title":"Exposure to the sun and sunbeds and the risk of cutaneous melanoma in the UK: A case\u2013control study","volume":"40","author":"Bataille","year":"2004","journal-title":"Eur. J. Cancer"},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1002\/ijc.21001","article-title":"Pigmentary characteristics and moles in relation to melanoma risk","volume":"116","author":"Perry","year":"2005","journal-title":"Int. J. Cancer"},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1002\/1097-0142(19900715)66:2<387::AID-CNCR2820660232>3.0.CO;2-J","article-title":"Count of benign melanocytic nevi as a major indicator of risk for nonfamilial nodular and superficial spreading melanoma","volume":"66","author":"JGrob","year":"1990","journal-title":"Cancer"},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1002\/ijc.2910620403","article-title":"Risk of cutaneous melanoma associated with a family history of the disease","volume":"62","author":"Ford","year":"1995","journal-title":"Int. J. Cancer"},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"757","DOI":"10.1016\/j.jaad.2009.07.039","article-title":"Risk of second primary malignancies following cutaneous melanoma diagnosis: A population-based study","volume":"62","author":"Spanogle","year":"2010","journal-title":"J. Am. Acad. Dermatol."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"1149","DOI":"10.1111\/ijd.14026","article-title":"Socioeconomic status and survival for patients with melanoma in the United States: An NCDB analysis","volume":"57","author":"Sitenga","year":"2018","journal-title":"Int. J. Dermatol."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"1664","DOI":"10.1002\/(SICI)1097-0142(19981015)83:8<1664::AID-CNCR23>3.0.CO;2-G","article-title":"The National Cancer Data Base report on cutaneous and noncutaneous melanoma","volume":"83","author":"Chang","year":"1998","journal-title":"Cancer"},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"1012","DOI":"10.1016\/j.jaad.2020.05.088","article-title":"Shorter survival and later stage at diagnosis among unmarried patients with cutaneous melanoma: A US national and tertiary care center study","volume":"83","author":"Rachidi","year":"2020","journal-title":"J. Am. Acad. Dermatol."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1007\/s40257-019-00487-x","article-title":"Malignant Melanoma of the Vulva and Vagina: A US Population-Based Study of 1863 Patients","volume":"21","author":"Wohlmuth","year":"2020","journal-title":"Am. J. Clin. Dermatol."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"131","DOI":"10.3322\/canjclin.54.3.131","article-title":"An evidence-based staging system for cutaneous melanoma","volume":"54","author":"Balch","year":"2004","journal-title":"CA A Cancer J. Clin."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"719","DOI":"10.1016\/j.jaad.2008.10.065","article-title":"Strategies for early melanoma detection: Approaches to the patient with nevi","volume":"60","author":"Goodson","year":"2009","journal-title":"J. Am. Acad. Dermatol."},{"key":"ref_15","first-page":"23","article-title":"Mitotic activity in non-neoplastic melanocytes in vivo","volume":"66","author":"September","year":"1975","journal-title":"Prospects"},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1016\/j.cell.2012.06.024","article-title":"A Landscape of Driver Mutations in Melanoma","volume":"150","author":"Hodis","year":"2012","journal-title":"Cell"},{"key":"ref_17","unstructured":"The Cancer Genome Atlas Network (2015). Genomic Classification of Cutaneous Melanoma. Cell, 161, 1681\u20131696."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"1382","DOI":"10.4161\/cc.4.10.2026","article-title":"Analysis of BRAF Mutation in Primary and Metastatic Melanoma Brief Report ABBREVIATIONS ND KEY WORDS ES CE INTRODUCTION RIB","volume":"4","author":"Libra","year":"2005","journal-title":"Cell Cycle"},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"330","DOI":"10.1111\/j.1600-0463.2011.02737.x","article-title":"KIT amplification and gene mutations in acral\/mucosal melanoma in Korea","volume":"119","author":"Yun","year":"2011","journal-title":"APMIS"},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1016\/j.semcancer.2019.09.013","article-title":"The mutational landscape of mucosal melanoma","volume":"61","author":"Nassar","year":"2020","journal-title":"Semin. Cancer Biol."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"1033","DOI":"10.1016\/j.celrep.2015.09.053","article-title":"Cancer-Associated SF3B1 Hotspot Mutations Induce Cryptic 3\u2032 Splice Site Selection through Use of a Different Branch Point","volume":"13","author":"Darman","year":"2015","journal-title":"Cell Rep."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1097\/CMR.0000000000000345","article-title":"Whole-exome sequencing identifies recurrent SF3B1 R625 mutation and comutation of NF1 and KIT in mucosal melanoma","volume":"27","author":"Hintzsche","year":"2017","journal-title":"Melanoma Res."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"930","DOI":"10.18632\/oncotarget.26584","article-title":"Recurrent hotspot SF3B1 mutations at codon 625 in vulvovaginal mucosal melanoma identified in a study of 27 Australian mucosal melanomas","volume":"10","author":"Quek","year":"2019","journal-title":"Oncotarget"},{"key":"ref_24","first-page":"7335","article-title":"Constitutive activation of Akt\/protein kinase B in melanoma leads to up-regulation of nuclear factor-\u03baB and tumor progression","volume":"62","author":"Dhawan","year":"2002","journal-title":"Cancer Res."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"1018","DOI":"10.1158\/1078-0432.CCR-15-1110","article-title":"Analysis of mTOR Gene Aberrations in Melanoma Patients and Evaluation of Their Sensitivity to PI3K\u2013AKT\u2013mTOR Pathway Inhibitors","volume":"22","author":"Kong","year":"2016","journal-title":"Clin. Cancer Res."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"3113","DOI":"10.1038\/sj.onc.1206451","article-title":"PTEN signaling pathways in melanoma","volume":"22","author":"Wu","year":"2003","journal-title":"Oncogene"},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"1189","DOI":"10.1016\/j.celrep.2017.04.031","article-title":"Interferon Receptor Signaling Pathways Regulating PD-L1 and PD-L2 Expression","volume":"19","author":"Shin","year":"2017","journal-title":"Cell Rep."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"1027","DOI":"10.1084\/jem.192.7.1027","article-title":"Engagement of the Pd-1 Immunoinhibitory Receptor by a Novel B7 Family Member Leads to Negative Regulation of Lymphocyte Activation","volume":"192","author":"Freeman","year":"2000","journal-title":"J. Exp. Med."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"1101","DOI":"10.1002\/cncr.10775","article-title":"Immunomodulatory effects of high-dose and low-dose interferon ?2b in patients with high-risk resected melanoma","volume":"95","author":"Kirkwood","year":"2002","journal-title":"Cancer"},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"170","DOI":"10.1016\/0090-8258(92)90250-M","article-title":"A clinicopathological study of 30 melanomas of the vulva","volume":"46","author":"Tasseron","year":"1992","journal-title":"Gynecol. Oncol."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"612","DOI":"10.1016\/j.ygyno.2011.04.007","article-title":"Malignant melanoma of the vulva: An extension of cutaneous melanoma?","volume":"122","author":"Moxley","year":"2011","journal-title":"Gynecol. Oncol."},{"key":"ref_32","unstructured":"(2022, August 30). Cancer-1 March 1993-Ragnarsson-Olding-Malignant Melanoma of the Vulva and Vagina Trends in Incidence Age.pdf. Available online: https:\/\/acsjournals.onlinelibrary.wiley.com\/doi\/abs\/10.1002\/1097-0142(19930301)71:5%3C1893::AID-CNCR2820710528%3E3.0.CO;2-7."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"1225","DOI":"10.1016\/0002-9378(94)90137-6","article-title":"Malignant melanoma of the vulva and vagina in the United States: Patterns of incidence and popu lation-based estimates of survival","volume":"171","author":"Weinstock","year":"1994","journal-title":"Am. J. Obstet. Gynecol."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"1118","DOI":"10.1097\/IGC.0b013e3182980ffb","article-title":"Vulvar\/Vaginal Melanoma","volume":"23","author":"Mert","year":"2013","journal-title":"Int. J. Gynecol. Cancer"},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"4340","DOI":"10.1200\/JCO.2006.06.2984","article-title":"Somatic Activation of KIT in Distinct Subtypes of Melanoma","volume":"24","author":"Curtin","year":"2006","journal-title":"J. Clin. Oncol."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"486","DOI":"10.1016\/j.humpath.2005.03.015","article-title":"Human malignant melanoma: Detection of BRAF- and c-kit\u2013activating mutations by high-resolution amplicon melting analysis","volume":"36","author":"Holden","year":"2005","journal-title":"Hum. Pathol."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"1333","DOI":"10.1002\/cncr.30473","article-title":"Vulvar and vaginal melanoma: A unique subclass of mucosal melanoma based on a comprehensive molecular analysis of 51 cases compared with 2253 cases of nongynecologic melanoma","volume":"123","author":"Hou","year":"2017","journal-title":"Cancer"},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1016\/j.ygyno.2017.08.023","article-title":"Gynecologic melanomas: A clinicopathologic and molecular analysis","volume":"147","author":"Udager","year":"2017","journal-title":"Gynecol. Oncol."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"1386","DOI":"10.1038\/modpathol.2013.211","article-title":"Comparison of molecular abnormalities in vulvar and vaginal melanomas","volume":"27","author":"Aulmann","year":"2014","journal-title":"Mod. Pathol."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"639","DOI":"10.1007\/s40257-021-00614-7","article-title":"Vulvar Melanoma: Molecular Characteristics, Diagnosis, Surgical Management, and Medical Treatment","volume":"22","author":"Wohlmuth","year":"2021","journal-title":"Am. J. Clin. Dermatol."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1016\/j.ygyno.2014.04.056","article-title":"NRAS mutations are more prevalent than KIT mutations in melanoma of the female urogenital tract\u2014A study of 24 cases from the Netherlands","volume":"134","author":"Grunsven","year":"2014","journal-title":"Gynecol. Oncol."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"477","DOI":"10.1097\/PGP.0000000000000454","article-title":"Frequent PD-L1 Expression in Malignant Melanomas of the Vulva","volume":"37","author":"Saleh","year":"2018","journal-title":"Int. J. Gynecol. Pathol."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"e291","DOI":"10.1634\/theoncologist.2019-0148","article-title":"Prevalence of NRAS Mutation, PD-L1 Expression and Amplification, and Overall Survival Analysis in 36 Primary Vaginal Melanomas","volume":"25","author":"Wang","year":"2020","journal-title":"Oncologist"},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"3111","DOI":"10.4161\/21645515.2014.983409","article-title":"PD-1 and PD-L1 antibodies for melanoma","volume":"10","author":"Tsai","year":"2014","journal-title":"Hum. Vaccines Immunother."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1056\/NEJMoa1504030","article-title":"Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma","volume":"373","author":"Larkin","year":"2015","journal-title":"N. Engl. J. Med."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1056\/NEJMoa1302369","article-title":"Nivolumab plus Ipilimumab in Advanced Melanoma","volume":"369","author":"Wolchok","year":"2013","journal-title":"N. Engl. J. Med."},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"1345","DOI":"10.1056\/NEJMoa1709684","article-title":"Overall Survival with Combined Nivolumab and Ipilimumab in Advanced Melanoma","volume":"377","author":"Wolchok","year":"2017","journal-title":"N. Engl. J. Med."},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"1535","DOI":"10.1056\/NEJMoa1910836","article-title":"Five-Year Survival with Combined Nivolumab and Ipilimumab in Advanced Melanoma","volume":"381","author":"Larkin","year":"2019","journal-title":"N. Engl. J. Med."},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"320","DOI":"10.1056\/NEJMoa1412082","article-title":"Nivolumab in Previously Untreated Melanoma without BRAF Mutation","volume":"372","author":"Robert","year":"2015","journal-title":"N. Engl. J. Med."},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"316","DOI":"10.1136\/jmedgenet-2018-105610","article-title":"Efficacy of novel immunotherapy regimens in patients with metastatic melanoma with germline CDKN2A mutations","volume":"57","author":"Helgadottir","year":"2020","journal-title":"J. Med. Genet."},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"4025","DOI":"10.1158\/1078-0432.CCR-21-0575","article-title":"CDKN2A Alterations and Response to Immunotherapy in Solid Tumors","volume":"27","author":"Adib","year":"2021","journal-title":"Clin. Cancer Res."},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"677","DOI":"10.1093\/jnci\/djx271","article-title":"Tumor CDKN2A-Associated JAK2 Loss and Susceptibility to Immunotherapy Resistance","volume":"110","author":"Horn","year":"2018","journal-title":"JNCI: J. Natl. Cancer Inst."},{"key":"ref_53","doi-asserted-by":"crossref","unstructured":"DeLeon, T.T., Almquist, D.R., Kipp, B.R., Langlais, B.T., Mangold, A., Winters, J.L., Kosiorek, H.E., Joseph, R.W., Dronca, R.S., and Block, M.S. (2020). Assessment of clinical outcomes with immune checkpoint inhibitor therapy in melanoma patients with CDKN2A and TP53 pathogenic mutations. PLoS ONE, 15.","DOI":"10.1371\/journal.pone.0230306"},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1016\/j.ejca.2018.04.010","article-title":"MEK inhibition may increase survival of NRAS-mutated melanoma patients treated with checkpoint blockade: Results of a retrospective multicentre analysis of 364 patients","volume":"98","author":"Kirchberger","year":"2018","journal-title":"Eur. J. Cancer"},{"key":"ref_55","first-page":"1310","article-title":"Improved antitumor activity of immunotherapy with BRAF and MEK inhibitors in BRAFV600E melanoma","volume":"17","year":"2012","journal-title":"Cancer"},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"3925","DOI":"10.1200\/JCO.20.02110","article-title":"Longer Follow-Up Confirms Recurrence-Free Survival Benefit of Adjuvant Pembrolizumab in High-Risk Stage III Melanoma: Updated Results From the EORTC 1325-MG\/KEYNOTE-054 Trial","volume":"38","author":"Eggermont","year":"2020","journal-title":"J. Clin. Oncol."},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"1239","DOI":"10.1016\/S1470-2045(19)30388-2","article-title":"Pembrolizumab versus ipilimumab in advanced melanoma (KEYNOTE-006): Post-hoc 5-year results from an open-label, multicentre, randomised, controlled, phase 3 study","volume":"20","author":"Robert","year":"2019","journal-title":"Lancet Oncol."},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1016\/j.ejca.2017.08.032","article-title":"Patient-reported outcomes in KEYNOTE-006, a randomised study of pembrolizumab versus ipilimumab in patients with advanced melanoma","volume":"86","author":"Petrella","year":"2017","journal-title":"Eur. J. Cancer"},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"236","DOI":"10.1016\/j.ejca.2018.06.034","article-title":"Outcomes by line of therapy and programmed death ligand 1 expression in patients with advanced melanoma treated with pembrolizumab or ipilimumab in KEYNOTE-006: A randomised clinical trial","volume":"101","author":"Carlino","year":"2018","journal-title":"Eur. J. Cancer"},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"v434","DOI":"10.1093\/annonc\/mdx377.011","article-title":"Analysis of response and survival in patients (pts) with ipilimumab (ipi)-refractory melanoma treated with pembrolizumab (pembro) in KEYNOTE-002","volume":"28","author":"Daud","year":"2017","journal-title":"Ann. Oncol."},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1016\/j.ejca.2016.07.018","article-title":"Health-related quality of life in the randomised KEYNOTE-002 study of pembrolizumab versus chemotherapy in patients with ipilimumab-refractory melanoma","volume":"67","author":"Schadendorf","year":"2016","journal-title":"Eur. J. Cancer"},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"908","DOI":"10.1016\/S1470-2045(15)00083-2","article-title":"Pembrolizumab versus investigator-choice chemotherapy for ipilimumab-refractory melanoma (KEYNOTE-002): A randomised, controlled, phase 2 trial","volume":"16","author":"Ribas","year":"2015","journal-title":"Lancet Oncol."},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"e66","DOI":"10.3802\/jgo.2020.31.e66","article-title":"Vulvar melanoma: An analysis of prognostic factors and treatment patterns","volume":"31","author":"Albert","year":"2020","journal-title":"J. Gynecol. Oncol."},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"226","DOI":"10.1200\/JCO.2016.67.9258","article-title":"Efficacy and Safety of Nivolumab Alone or in Combination With Ipilimumab in Patients With Mucosal Melanoma: A Pooled Analysis","volume":"35","author":"Larkin","year":"2017","journal-title":"J. Clin. Oncol."},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"670","DOI":"10.1038\/s41416-018-0207-6","article-title":"Antitumour activity of pembrolizumab in advanced mucosal melanoma: A post-hoc analysis of KEYNOTE-001, 002, 006","volume":"119","author":"Hamid","year":"2018","journal-title":"Br. J. Cancer"},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"999","DOI":"10.21873\/anticanres.14854","article-title":"Lower Genital Tract Melanomas: Staging, Predictors of Outcome, and New Therapeutic Options","volume":"41","author":"Egger","year":"2021","journal-title":"Anticancer Res."},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"373","DOI":"10.3892\/mco.2017.1158","article-title":"A retrospective clinical analysis of 5 cases of vaginal melanoma","volume":"6","author":"Tasaka","year":"2017","journal-title":"Mol. Clin. Oncol."},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"S33","DOI":"10.1016\/S0090-8258(21)00708-3","article-title":"Too much skin in the game? A paradigm shift in our understanding of vulvar and vaginal melanomas as distinct tumor types compared with cutaneous melanomas","volume":"162","author":"Wilhite","year":"2021","journal-title":"Gynecol. Oncol."},{"key":"ref_69","unstructured":"Skovsted, S., Nielsen, K., and Blaak\u00e6r, J. (2017). Melanomas of the vulva and vagina. Dan. Med. J., 64."},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1016\/j.ygyno.2021.01.018","article-title":"Evaluation of treatment, prognostic factors, and survival in 198 vulvar melanoma patients: Implications for clinical practice","volume":"161","author":"Boer","year":"2021","journal-title":"Gynecol. Oncol."},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1111\/ijlh.12426","article-title":"The DULCIS (D-Dimer-ULtrasonography In Combination Italian Study) Investigators. Comparison between different D-Dimer cutoff values to assess the individual risk of recurrent venous thromboembolism: Analysis of results obtained in the DULCIS study","volume":"38","author":"Palareti","year":"2016","journal-title":"Int. J. Lab. Hematol."},{"key":"ref_72","doi-asserted-by":"crossref","first-page":"176","DOI":"10.1016\/j.humpath.2017.12.022","article-title":"Prognostic role of tumoral PDL1 expression and peritumoral FoxP3+ lymphocytes in vulvar melanomas","volume":"73","author":"Selim","year":"2018","journal-title":"Hum. Pathol."},{"key":"ref_73","doi-asserted-by":"crossref","first-page":"e94","DOI":"10.3802\/jgo.2019.30.e94","article-title":"Investigating the role of immunotherapy in advanced\/recurrent female genital tract melanoma: A preliminary experience","volume":"30","author":"Indini","year":"2019","journal-title":"J. Gynecol. Oncol."},{"key":"ref_74","doi-asserted-by":"crossref","first-page":"645","DOI":"10.1016\/j.ygyno.2021.03.017","article-title":"Immunotherapy combined with high- and low-dose radiation to all sites leads to complete clearance of disease in a patient with metastatic vaginal melanoma","volume":"161","author":"Sezen","year":"2021","journal-title":"Gynecol. Oncol."},{"key":"ref_75","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1177\/0300060520965398","article-title":"Multiple metastases after surgery for a rare vulvar malignant melanoma combined with immunotherapy: A case report","volume":"48","author":"Li","year":"2020","journal-title":"J. Int. Med. Res."},{"key":"ref_76","doi-asserted-by":"crossref","first-page":"e4","DOI":"10.1097\/LGT.0000000000000168","article-title":"Locally Advanced Unresectable Vaginal Melanoma: Response With Anti\u2013Programmed Death Receptor 1","volume":"20","author":"Chanal","year":"2016","journal-title":"J. Low. Genit. Tract Dis."}],"container-title":["Cancers"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2072-6694\/14\/20\/5123\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T00:57:24Z","timestamp":1760144244000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2072-6694\/14\/20\/5123"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,10,19]]},"references-count":76,"journal-issue":{"issue":"20","published-online":{"date-parts":[[2022,10]]}},"alternative-id":["cancers14205123"],"URL":"https:\/\/doi.org\/10.3390\/cancers14205123","relation":{},"ISSN":["2072-6694"],"issn-type":[{"value":"2072-6694","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,10,19]]}}}